Alexander E. Drilon, MD, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers and <em>RET</em>-mutant medullary thyroid cancers.
Alexander E. Drilon, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers andRET-mutant medullary thyroid cancers (MTC).
Behind the FDA Approval: Momelotinib for Myelofibrosis and Anemia
September 20th 2023In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, delves further into the background of momelotinib, how to manage toxicities with the agent, and its role in clinical practice moving forward.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Emerging CAR T-Cell Therapies in Large B-Cell Lymphoma
September 13th 2023In an interview with Targeted Oncology, Frederick Locke, MD, discussed the mechanism of action of 2 allogeneic CD19-directed CAR T-cell products and next steps for their evaluation for the treatment of patients with LBCL.
Read More
Ivaltinostat Combinations Show Promise for Pancreatic Adenocarcinoma
September 13th 2023In an interview, Mohamad Adham Salkeni, MD, FRCPC, discussed the ongoing study of maintenance ivaltinostat plus capecitabine or capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line FOLFIRINOX.
Read More
2 Clarke Drive
Cranbury, NJ 08512